Combination drug therapy halts disease in advanced melanoma
29 September 2014
A world-first study in the New England Journal of Medicine heralds the effectiveness of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic melanoma.
The multi-centre, double-blind, randomised, phase 3 trial compared oral dabrafenib (150 mg twice daily) and oral trametinib (2 mg once daily) combination therapy with oral dabrafenib (150 mg twice daily) and placebo.
Led by Associate Professor Georgina Long of Melanoma Institute Australia and The University of Sydney, the finding affirms accumulating evidence of the effectiveness of targeted combination therapies in extending life and halting disease progression in patients with cancers that carry genetic mutations that resist single-drug therapies.
“We show a significant 25 per cent reduction in the risk of disease progression with the combination of dabrafenib and trametinib over single-agent dabrafenib,” says Assistant Professor Long.
“We also report a significant 37 per cent relative reduction in the risk of death among people who received the combination drug therapy compared with monotherapy.”
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.